LEAH Labs

LEAH Labs is pioneering the development of living therapies, initially targeting pets and subsequently expanding to human applications. Their primary focus is on CAR-T cell therapy for dogs suffering from B cell lymphoma, a naturally occurring condition closely resembling human non-Hodgkin's lymphoma. CAR-T cell therapies have demonstrated curative potential in humans, and LEAH Labs' preliminary results suggest similar efficacy in pets, with observed remissions in advanced-stage lymphoma cases. Their innovative, virus-free gene editing platform enables the production of a CAR-T cell therapy dose at an approximate cost of $500, offering the prospect of a curative outcome. With promising safety and efficacy data, LEAH Labs envisions widespread adoption of their product by general practice veterinarians across the United States, who currently rely on palliative care or refer cancer patients to specialized oncologists. The CAR-T cell platform operates under the regulatory oversight of the USDA, rather than the FDA, providing a cost-effective and integrated framework for iterative development and clinical validation of CAR-T cell therapies, from initial hypothesis to clinical application.